Lv31
206 积分 2024-05-09 加入
Anti-IGF-1R antisense oligonucleotide CT102: A promising therapeutic agent for graves' ophthalmopathy
5分钟前
求助中
THRIVE
14分钟前
求助中
Lonigutamab inhibits hyaluronan production by reducing IGF-1R levels in thyroid eye disease orbital fibroblasts
22分钟前
已完结
Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease
25分钟前
已完结
Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: A nationwide retrospective study
58分钟前
已完结
The Epidemiology of Thyroid Eye Disease in Olmsted County, Minnesota 2005-2020
1小时前
已完结
Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease
4天前
已完结
Fluoropolymer‐Mediated Delivery of a Dual TSHR/IGF1R‐Targeting CRISPR‐Cas9 System for Localized Therapy in Thyroid‐Associated Ophthalmopathy
9天前
已完结
Bispecific aptamers target thyrotropin receptor (TSHR) and insulin growth factor-1 receptor (IGF-1R) for the improvement of orbital fibroblasts activation in the treatment of thyroid-associated ophthalmopathy
9天前
已完结
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
10天前
已完结
皖公网安备34019202002308
